Financials in USD. Standardized financial statements.
A compact view of how Integrated BioPharma, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $54.35M | $50.32M | $50.67M | $56.25M | $63.56M | $52.77M | $49.98M | $43.71M | $46.95M | $42.21M |
| Revenue Growth? | +8.0% | -0.7% | -9.9% | -11.5% | +20.4% | +5.6% | +14.3% | -6.9% | +11.2% | 0.0% |
| Cost of Revenue? | $48.79M | $46.43M | $46.61M | $49.69M | $54.08M | $46.04M | $43.76M | $38.72M | $40.29M | $36.71M |
| Gross Profit? | $5.56M | $3.88M | $4.06M | $6.55M | $9.48M | $6.73M | $6.22M | $4.99M | $6.67M | $5.50M |
| Gross Margin? | +10.2% | +7.7% | +8.0% | +11.6% | +14.9% | +12.7% | +12.4% | +11.4% | +14.2% | +13.0% |
| Operating Expenses? | $3.54M | $3.63M | $3.94M | $3.81M | $3.70M | $3.47M | $3.52M | $3.29M | $3.48M | $3.39M |
| Operating Income? | $2.02M | $251,000 | $120,000 | $1.97M | $5.78M | $2.38M | $2.70M | $1.69M | $3.19M | $2.11M |
| EBITDA? | $3.38M | $1.47M | $1.27M | $3.56M | $6.61M | $4.26M | $3.48M | $2.28M | $3.58M | $2.87M |
| Income Before Tax | $2.06M | $268,000 | $100,000 | $2.60M | $7.25M | $3.09M | $2.04M | $1.00M | $1.86M | $1.19M |
| Income Tax Expense | $1.25M | $156,000 | $134,000 | -$1.24M | -$766,000 | -$1.02M | $354,000 | $326,000 | -$490,000 | $231,000 |
| Net Income? | $808,000 | $112,000 | -$34,000 | $3.84M | $8.01M | $4.11M | $1.69M | $679,000 | $2.35M | $958,000 |
| EPS? | $0.03 | $0.00 | $-0.00 | $0.13 | $0.27 | $0.14 | $0.06 | $0.02 | $0.11 | $0.05 |
| Diluted EPS? | $0.03 | $0.00 | $-0.00 | $0.12 | $0.25 | $0.13 | $0.06 | $0.02 | $0.10 | $0.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality